Evidence map›Paper›PMID 39343859›Full record

ArticleCurrent microbiology2024

Immunogenicity of Brucella Trivalent Immunogen-Containing Polyethyleneimine Nanostructure Targeted with LPS in a Mouse Model.

Mansoureh Iranikhah, Razieh Nazari, Mahdi Fasihi-Ramandi, Ramezan Ali Taheri, Mohsen Zargar

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mansoureh IranikhahDepartment of Microbiology, Qom Branch, Islamic Azad University, Qom, Iran.ORCID http://orcid.org/0009-0008-3185-0645
Razieh NazariDepartment of Microbiology, Qom Branch, Islamic Azad University, Qom, Iran. razieh.nazari@iau.ac.ir.ORCID http://orcid.org/0000-0003-4819-5735
Mahdi Fasihi-RamandiMolecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-8242-4880
Ramezan Ali TaheriNanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tahran, Iran.ORCID http://orcid.org/0000-0003-1394-6412
Mohsen ZargarDepartment of Microbiology, Qom Branch, Islamic Azad University, Qom, Iran.ORCID http://orcid.org/0000-0002-3108-5655

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brucella is a facultative intracellular gram-negative coccobacillus. It is nonsporulating and reproduced in macrophage phagosomes. The use of nanostructures as drug and vaccine carriers has recently received attention due to their ability to control the release profile and protect the drug molecules. This study presents a suitable nano-polyethyleneimine formulation to be used as an immunoadjuvant and LPS along with trivalent candidate antigens of TF, BP26, and omp31 to selectively stimulate the immune response. After designing and evaluating the immunogenic structure by databases and bioinformatics software, recombinant protein cloning and gene expression were performed in Escherichia coli BL21 bacteria. This protein was extracted from the cultured cells, purified by Ni-NTA column. After placing the antigen inside the polyethyleneimine nanostructure, various properties of the nanoparticles, including their size, zeta potential, and retention rate for injection and inhalation of mice, diffusion efficacy, and antigen binding evaluation were evaluated. Mice were treated with different groups of antigens and nanoparticles on days 0, 10, 24, and 38. Two weeks after the last injection, the level of cytokines were investigated in spleen cells, including IFN-γ, IL-4, and IL-12. The serum concentration of IgG2a and IgG1 antibodies were also assessed. The response was consistent with significant production of IgG1, IgG2a, IFN-γ21, IL-12, and IL-4 compared to the controls (P < 0.05). Compared to the positive and negative control groups, recombinant protein and nanoparticles showed a good response in subsequent injections with live bacterial strains. The present study also revealed the potential of the developed recombinant protein as a candidate in the design and manufacture of subunit vaccines against Brucella species. This protein stimulates cellular and humoral immune responses compared to the positive control groups. These findings can be useful in the prevention and control of brucellosis and pave the way for further research by researchers around the world.

Indexed as

Antibodies, BacterialAntigens, BacterialBrucellaBrucellosisLipopolysaccharidesPolyethyleneimineAdjuvants, ImmunologicAnimalsBacterial Outer Membrane ProteinsBacterial ProteinsBrucella VaccineCytokinesDisease Models, AnimalFemaleImmunoglobulin GMembrane ProteinsAdjuvants, ImmunologicAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsBacterial ProteinsBP26 protein, BrucellaBrucella VaccineCytokinesImmunoglobulin GLipopolysaccharidesMembrane ProteinsOmp31 protein, Brucella melitensisPolyethyleneimine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.